Navigation Links
NCE in Biological Technology

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value

...tory and cardio-metabolic disease. Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary nce and the first Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) anti-inflammatory agent for the treatment of the signs and symptoms of osteoarth...

NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance

...ory and cardio-metabolic disease. Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary nce and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs...

Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Research Forward

...OACH TO IMI PLANNED Under the terms of the agreement, Oslo Cancer Cluster nce with Cancer-Bio-Sante Cluster and Toulouse Canceropole commit to cooperate ...ion in Atlanta. More information: Bjarte Reve, CEO, Oslo Cancer Cluster nce - cellphone: +47-971-09-585. Jean-Pierre Saintouil, CEO, Toulouse Cancer-...

SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R)

...ndent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. The most advanced nce is SVT-40776 for the treatment of Overactive Bladder, which has recently finished phase II. In 2007 SALVAT's products were distributed in more than 30...

New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)

...ion of new kinase inhibitors." Dr David Bailey, heading IOTA, commented, "Fragment-based drug discovery is a fast, efficient and productive route to nce discovery. Our combined technologies offer a comprehensive lead discovery solution to our pharma partners." About IOTA IOTA Pharmaceuticals provid...

ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials

...efforts of the Allergan and ExonHit research team, human clinical testing will be initiated on the first collaboration New Chemical Entity (NCE). This nce (designated EHT/AGN001) has a novel mechanism of action and will enter a phase I study later this year. The objectives of Allergan and ExonHit's stra...

Midwest Investment Bank Piper Jaffray Resurges in New York City

... 505(b)(2) pathway receive Waxman-Hatch market exclusivity (equivalent to patent protection) for three years for new labeling, up to five years for an nce and seven years under orphan drug designation. While this is not of great interest to Big Pharma because market exclusivity is too short, it is of gre...
Other Tags
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
(Date:3/3/2015)... (PRWEB) March 03, 2015 Aurora Fit ... celebration and charity drive to observe the opening of the ... charity organization Ashleigh’s Hope. The event will be held on ... S #7, Aurora, ON. The opening will feature free boot ... Fit Body Boot Camp is the world’s most popular and ...
(Date:3/2/2015)... Formetco today announced the official launch ... FTX uses state-of-the-art technology to deliver an outdoor advertising ... satisfaction. An item of particular value, and previously ... year LED Brightness Warranty. , Why the FTX was ... billboard among any other billboard product in the world. ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Dr. David ... injury, is partnering with Doctors on Liens ... patients. It’s rare for personal injury victims to ... and especially on a lien basis. However, San ... outstanding team of chiropractors, M.D., pain management physician, massage, ...
(Date:3/2/2015)... New York, NY (PRWEB) March 02, 2015 ... a long history of catalyzing private sector activities ... that it has recently elected four new members ... , GBCHealth welcomes Dr. Paul Farmer, Chief Strategist ... University Professor at Harvard University; Dr. Huma Abbasi, ...
(Date:3/2/2015)... 02, 2015 “ Wants and Needs ... monthly AppWatch, which features the latest and coolest mobile ... Tropeano, a mobile technology expert and host of NewsWatch, ... this app helps people evaluate priorities. , Whether a ... Wants and Needs app. The app allows people to ...
Breaking Medicine News(10 mins):Health News:Aurora Fit Body Boot Camp Celebrates Grand Opening with Charity Fundraiser 2Health News:Aurora Fit Body Boot Camp Celebrates Grand Opening with Charity Fundraiser 3Health News:Formetco Launches Innovative LED Billboard System 2Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2
Other Contents